By Application
Hot products 
-
Mouse Anti-ALB Recombinant Antibody (V2-180650) (CBMAB-A2186-YC)
-
Mouse Anti-ATP1B1 Recombinant Antibody (E4) (CBMAB-0463-LY)
-
Mouse Anti-DLL4 Recombinant Antibody (D1090) (CBMAB-D1090-YC)
-
Mouse Anti-CD164 Recombinant Antibody (CBFYC-0077) (CBMAB-C0086-FY)
-
Mouse Anti-8-oxoguanine Recombinant Antibody (V2-7719) (CBMAB-1898CQ)
-
Mouse Anti-CD2AP Recombinant Antibody (BR083) (CBMAB-BR083LY)
-
Rabbit Anti-CCL5 Recombinant Antibody (R0437) (CBMAB-R0437-CN)
-
Mouse Anti-ADGRE5 Recombinant Antibody (V2-360335) (CBMAB-C2088-CQ)
-
Mouse Anti-BIRC5 Recombinant Antibody (6E4) (CBMAB-CP2646-LY)
-
Mouse Anti-DDC Recombinant Antibody (8E8) (CBMAB-0992-YC)
-
Mouse Anti-2C TCR Recombinant Antibody (V2-1556) (CBMAB-0951-LY)
-
Mouse Anti-BAX Recombinant Antibody (CBYY-0216) (CBMAB-0217-YY)
-
Mouse Anti-DLG1 Monolconal Antibody (4F3) (CBMAB-0225-CN)
-
Mouse Anti-ADAM12 Recombinant Antibody (V2-179752) (CBMAB-A1114-YC)
-
Mouse Anti-AK4 Recombinant Antibody (V2-180419) (CBMAB-A1891-YC)
-
Mouse Anti-AKT1 Recombinant Antibody (V2-180546) (CBMAB-A2070-YC)
-
Mouse Anti-ATP1B3 Recombinant Antibody (1E9) (CBMAB-A4021-YC)
-
Rabbit Anti-B2M Recombinant Antibody (CBYY-0059) (CBMAB-0059-YY)
-
Mouse Anti-AQP2 Recombinant Antibody (G-3) (CBMAB-A3359-YC)
-
Mouse Anti-ADAM29 Recombinant Antibody (V2-179787) (CBMAB-A1149-YC)
Cervical Cancer
Fig.1 Cervical cancer
Cervical cancer is a cancer originated from the cervix. Globally, cervical cancer is the fourth-most common cause of death from cancer among women and fourth-most common cause of cancer. At early stage, typically no symptoms are been found. However, later symptoms may include pelvic pain, vaginal bleeding, or pain during sexual intercourse. While bleeding after sex may not to be treated seriously, it may also reveal the presence of cervical cancer. Human papillomavirus (HPV) infection leads to about 90% of cases, followed by smoking. However, majority of people who have had HPV infections, do not develop cervical cancer. Cervical cancer typically develops from precancerous changes for 10 to 20 years. Around 90% of cervical cancer cases are diagnosed as squamous cell carcinomas, 10% are adenocarcinoma, and a small number are other types. Some novel prognostic markers, like TBLR1, MicroRNA-497, have been studied recently.
Loading...
Compare
